Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials.
Common medications like statins may improve immunotherapy outcomes in sarcoma, while others warrant careful monitoring.
In 321 sarcoma patients pooled from 7 MSK Phase II ICI trials, several concomitant medication classes showed significant associations with immunotherapy outcomes: statins improved PFS, anti-infectives shortened PFS, and opioids shortened OS. These pharmacological interactions may have implications for clinical trial stratification and patient counseling in sarcoma immunotherapy.
What the study was
- Study design
- Pooled post hoc analysis of seven Phase II trials
- Population
- Advanced or metastatic sarcoma patients receiving ICI-based therapy
- Sample size
- 321
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer Medicine
Why it surfaced
Large pooled analysis (n=321, 7 trials, MSK) identifying concomitant medication signals on ICI outcomes in sarcoma. Found via sentinel scan, not T6 watchlist search.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.